<DOC>
	<DOC>NCT00366379</DOC>
	<brief_summary>This study will assess the efficacy, safety and tolerability of increasing doses of GK Activator (2) in patients with type 2 diabetes whose condition has not been optimally controlled with one previous oral antihyperglycemic agent. After a 2 week washout from their previous antidiabetic therapy, patients will receive GK Activator (2) orally, twice a day for 12 weeks, at increasing doses of 25mg bid to 200mg bid; doses will be titrated to achieve a target fasting glucose level (FPG) of &lt;100mg/dL. The anticipated time on study treatment is &lt;3 months, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>adult patients, 1875 years of age; type 2 diabetes mellitus treated with one oral antihyperglycemic agent for &gt;=3 months prior to screening. type 1 diabetes mellitus; treatment with insulin, PPAR agonists or systemic corticosteroids during the 3 months prior to screening; women who are pregnant, breastfeeding or not using adequate contraceptive methods.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>